The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences.

Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.

×
Published Online:https://doi.org/10.1176/ps.43.2.107

Clinicians who treat patients with comorbid substance abuse and psychiatric disorders need both the expertise involved in treating each of the patient's individual disorders and the specialized knowledge required to help the patient cope with having more than one illness. Programs treating dually diagnosed patients should include sophisticated psychopharmacologic and psychotherapeutic treatment, offer the capability of safely detoxifying patients from a variety of different agents, include relapse prevention and 12-step techniques, and provide long-term treatment to help patients work through the difficulties they will experience at various stages of the recovery process. By combining excellent psychiatric and chemical dependence treatment, such specialized programs may be able to substantially improve the prognosis of a patient population that has traditionally been very difficult to reach.

Access content

To read the fulltext, please use one of the options below to sign in or purchase access.